title: Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide.
abstract: The present study was performed to determine experimental conditions for thalidomide induction of fetal malformations and to understand the molecular mechanisms underlying thalidomide teratogenicity in cynomolgus monkeys. Cynomolgus monkeys were orally administered thalidomide at 15 or 20mg/kg-d on days 26-28 of gestation, and fetuses were examined on day 100-102 of gestation. Limb defects such as micromelia/amelia, paw/foot hyperflexion, polydactyly, syndactyly, and brachydactyly were observed in seven of eight fetuses. Cynomolgus monkeys were orally administered thalidomide at 20mg/kg on day 26 of gestation, and whole embryos were removed from the dams 6h after administration. Three embryos each were obtained from the thalidomide-treated and control groups. Total RNA was isolated from individual embryos, amplified to biotinylated cRNA and hybridized to a custom Non-Human Primate (NHP) GeneChip((R)) Array. Altered genes were clustered into genes that were up-regulated (1281 genes) and down-regulated (1081 genes) in thalidomide-exposed embryos. Functional annotation by Gene Ontology (GO) categories revealed up-regulation of actin cytoskeletal remodeling and insulin signaling, and down-regulation of pathways for vasculature development and the inflammatory response. These findings show that thalidomide exposure perturbs a general program of morphoregulatory processes in the monkey embryo. Bioinformatics analysis of the embryonic transcriptome following maternal thalidomide exposure has now identified many key pathways implicated in thalidomide embryopathy, and has also revealed some novel processes that can help unravel the mechanism of this important developmental phenotype.
authors.affiliation: Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. ema@nihs.go.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Ema
authors.forename: Ryota
authors.initials: R
authors.lastname: Ise
authors.forename: Hirohito
authors.initials: H
authors.lastname: Kato
authors.forename: Satoru
authors.initials: S
authors.lastname: Oneda
authors.forename: Akihiko
authors.initials: A
authors.lastname: Hirose
authors.forename: Mutsuko
authors.initials: M
authors.lastname: Hirata-Koizumi
authors.forename: Amar V
authors.initials: AV
authors.lastname: Singh
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Knudsen
authors.forename: Toshio
authors.initials: T
authors.lastname: Ihara
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics*; D000818:Animals; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling / Q000662:veterinary; D005865:Gestational Age; D017880:Limb Deformities, Congenital / Q000139:chemically induced / Q000453:epidemiology; D008252:Macaca fascicularis / Q000196:embryology*; D008431:Maternal-Fetal Exchange; D046228:Microarray Analysis; D011247:Pregnancy; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D013723:Teratogens / Q000633:toxicity*; D013792:Thalidomide / Q000008:administration & dosage / Q000633:toxicity*
chemical_list: D013723:Teratogens; D013792:Thalidomide; D012313:RNA